ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Cerus Corp

Cerus Corp (CERS)

2.39
0.07
(3.02%)
Closed July 23 4:00PM
2.39
0.00
( 0.00% )
Pre Market: 7:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.39
Bid
2.26
Ask
2.45
Volume
-
0.00 Day's Range 0.00
1.205 52 Week Range 3.08
Market Cap
Previous Close
2.39
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
963,919
Shares Outstanding
184,890,071
Dividend Yield
-
PE Ratio
-11.79
Earnings Per Share (EPS)
-0.2
Revenue
186.8M
Net Profit
-37.49M

About Cerus Corp

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INT... Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. Show more

Sector
Surgical,med Instr,apparatus
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
2010
Cerus Corp is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CERS. The last closing price for Cerus was $2.39. Over the last year, Cerus shares have traded in a share price range of $ 1.205 to $ 3.08.

Cerus currently has 184,890,071 shares outstanding. The market capitalization of Cerus is $441.89 million. Cerus has a price to earnings ratio (PE ratio) of -11.79.

CERS Latest News

Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will...

Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell...

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus...

Cerus Corporation Celebrates World Blood Donor Day 2024

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.14.366812227072.292.472.1710332112.30820993CS
40.7142.26190476191.682.471.64510108772.09374405CS
120.7444.84848484851.652.471.629639191.91634216CS
260.5429.18918918921.852.5851.6112879061.97845878CS
52-0.49-17.01388888892.883.081.20512607791.89701552CS
156-2.6-52.10420841684.998.0551.20514183893.79037958CS
260-3.24-57.54884547075.6391.20515139514.70384582CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRMADermata Therapeutics Inc
$ 2.98
(129.23%)
10.15M
NUZENuZee Inc
$ 1.87
(81.55%)
2.16M
HOTHHoth Therapeutics Inc
$ 1.55
(59.47%)
4.43M
ALLRAllarity Therapeutics Inc
$ 0.2371
(42.40%)
26.55M
RGCRegencell Bioscience Holdings Ltd
$ 20.35
(36.03%)
356.7k
CONNConns Inc
$ 0.365
(-28.01%)
111.2k
VSTMVerastem Inc
$ 2.67
(-25.63%)
55.44k
TCBPTC BioPharm Holdings PLC
$ 0.60
(-25.00%)
502
ATPCAgape ATP Corporation
$ 0.1661
(-22.74%)
445.25k
SAGESage Therapeutics Inc
$ 10.20
(-22.02%)
560
ALLRAllarity Therapeutics Inc
$ 0.2371
(42.40%)
26.55M
DRMADermata Therapeutics Inc
$ 2.98
(129.23%)
10.15M
SLNASelina Hospitality PLC
$ 0.0274
(5.38%)
9.24M
HOTHHoth Therapeutics Inc
$ 1.55
(59.47%)
4.43M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.47
(-16.28%)
2.97M

CERS Discussion

View Posts
Eastwood Bets Eastwood Bets 2 months ago
This stock is on the move ...
Do NOT miss it before it takes off!!
Nearly 70% of of all analyst agree !
At 2 bucks your nuts 🥜 not to pick up some shares now !
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Awl416 Awl416 4 months ago
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
CERS new 52 week low
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
$CERS Book Value Per Share (mrq) ONLY $0.65
πŸ‘οΈ0
mogman mogman 4 years ago
Looks like CP using Intercept plasma will push the SP well over $7 and just could go over $20 if key metrics indicate a possible buy out. Since the closest competition Mirasol is now a non-starter with the FDA last week, CERS occupies a monopoly position. That is not to mention RBS approval in the next few years as well as the now released info that American Red Cross will not guarantee requested shipment fulfillment if Intercept is not stipulated. CERS now owns the market along with locked in distributors throughout the world. No brainer investment for the whole next decade. Even buying at $20 SP will be a 10 bagger in5 yeas or less. Probably less. Very long here.
πŸ‘οΈ0
Porterhouse10 Porterhouse10 4 years ago
Looking for entry, awesome growth and balance sheet, could be a good Covid play jmo
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $CERS Video Chart 02-13-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $CERS Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $CERS Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 6 years ago
CERS been in this play for 2 months now...time to make some noise!!!
πŸ‘οΈ0
cottonmather cottonmather 6 years ago
Longer term technical promise. http://stockcharts.com/public/1164099
πŸ‘οΈ0
mogman mogman 6 years ago
From Berkshire Hathaway's - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Recent developments and highlights include:

*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a

17% to 22% increase over 2017 reported product revenue.

*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.

IMO it is up from here and a buy at $5.
πŸ‘οΈ0
mogman mogman 6 years ago
NAVY Department worth more than today's 4 cent CERS SP rise. Description: Department of the Navy

Bureau of Medicine and Surgery

U.S. Naval Hospital Guam

US Naval Hospital Guam intends to award a sole-source drop-shipment contract under the authority of FAR 13, due to the only source available to meet the Government's needs, to Cerus Corporation, 2550 Stanwell Drive, Concord, CA 94520. Reference NAICS Code 325412. The following products will be procured: 0001. INTERCEPT Platelet Small Volume Processing Set, P/N INT2110B. Quantity: 8 Cases (2 cases to be delivered on March 2018, May 2018, July 2018, and Sep 2018). 0002. INTERCEPT Platelet Processing Set with Dual Storage Containers, P/N INT2510B. Quantity: 5 Cases (2 cases to be delivered on March 2018, 1 case to be delivered on May 2018, July 2018, and Sep 2018. This notice of intent is not a request for competitive proposals.

FULL INFO https://www.fbo.gov/spg/DON/BUMED/N68096/N6809618Q0008/listing.html

Time for a big thumbs up on that start!!
πŸ‘οΈ0
StockRacer87 StockRacer87 6 years ago
Shorts attacked it well today
πŸ‘οΈ0
QuidRunner QuidRunner 6 years ago
Good new out yesterday after regarding CERS trials. Stock is steadily moving UP!!!
πŸ‘οΈ0
lugan lugan 7 years ago
Yesterday, today and tomorrow!
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $CERS Video Chart 11-03-17 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Marvy Marvy 7 years ago
Big news!!!
πŸ‘οΈ0
jonnyvs jonnyvs 7 years ago
Is this today's bio play?
πŸ‘οΈ0
ResearchDD ResearchDD 7 years ago
What a joke!!!!!!!!!!!!!!!!!!!!!!! Played the Zika! Pump and now Dump!!!
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $CERS Video Chart 08-08-17 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Marvy Marvy 7 years ago
Employee buying?
πŸ‘οΈ0
BigTony1 BigTony1 7 years ago
you have to wait till tomorrow...
πŸ‘οΈ0
Marvy Marvy 7 years ago
Are things turning around?
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $CERS Video Chart 07-27-17 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Awesome A Awesome A 7 years ago
The frustrating thing with this stock is whenever there is good news (as we had recently) the increase in the stock price is de minimis. However, whenever there is the hint of bad news, the stock price falls through the floor.

When is the red blood cell treatment going to be ready for FDA approval? There has been far too many delays on this and right now this stock needs to show profits (forget about narrowing losses). Also, any news if this company is the target of a merger or takeover?
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $CERS Video Chart 06-07-17 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $CERS Video Chart 05-26-17 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
mdimport mdimport 7 years ago
I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.



Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."
πŸ‘οΈ0
starkd748 starkd748 7 years ago
Yea looks like that this one is done for awhile
πŸ‘οΈ0
kevinraugust25 kevinraugust25 7 years ago
Every chart I see from the point the stock starts falling to where it starts gaining steam again is 2-4 months... but mainly 2-3 months... now it may take 6 months to gain the ground it lost back.. but the bottom is around 2-3 months....
πŸ‘οΈ0
willlbone willlbone 7 years ago
Check the monthly charts. Every downtrend took about 6 months.
πŸ‘οΈ0
mdimport mdimport 7 years ago
Even with the oversold RSI? I was watching to see when there'd be a turn in the price and sentiment short-term.

Longer-term, I agree based on the announced delays.

Thanks for the inputs :)
πŸ‘οΈ0
willlbone willlbone 7 years ago
Price will drift downward for 6 months, then buy.
πŸ‘οΈ0
mdimport mdimport 7 years ago
Do you see this company recovering?
πŸ‘οΈ0
starkd748 starkd748 7 years ago
Yea might buy to flip easy money this thing has a ways to go....fda acting the same as ever lol
πŸ‘οΈ0
willlbone willlbone 7 years ago
Heading under $2.
πŸ‘οΈ0
wiltonio wiltonio 7 years ago
Elk Creek Partners, LLC has filed a new 13G, reporting 5.17% ownership in $CERS - https://fintel.io/so/us/cers
πŸ‘οΈ0
starkd748 starkd748 7 years ago
Its lower. ..glad I sold went to penny mmj plays best move i could hsvr made
πŸ‘οΈ0
ResearchDD ResearchDD 7 years ago
Waiting to buy CERS at 3.75 read my post April 4
πŸ‘οΈ0
ResearchDD ResearchDD 7 years ago
I will buy back at 3.75 not highter
πŸ‘οΈ0
Harpo1 Harpo1 7 years ago
Hi Guys,

Looks like they took the recent earnings on the chin. And

bounced back.....This should run when if France, South Africa

launch and or FDA final goes into law.
πŸ‘οΈ0
Harpo1 Harpo1 7 years ago
Hi Guys,

Yes they are slow in marketing and sales. But this sell off will

reward much to those who hold for 2 plus years.

Action point.


FDA Blood safety guidelines issued for this year implementation

in 2018,

Sales of Incercept to France, Canada, Africa, and South America
πŸ‘οΈ0
mogman mogman 7 years ago
Noted.
πŸ‘οΈ0
Harpo1 Harpo1 7 years ago
Hi Guys,

Looks like CERS issued some large bonus to key employees.

Looks bullish to me.

Earning after market closes on March 7, 2017.

Should test past highs!!!! And more. Several brokerage houses

have target prices $9-10.

With a lot more potential in the future!!!!
πŸ‘οΈ0
Harpo1 Harpo1 7 years ago
Hi Guys,

Really strange that CERS did not issue a press release with this detail study.

Something big must be up...........IMHO

Buying more here.
πŸ‘οΈ0
mogman mogman 7 years ago
Excerpts from

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full
See full text for abbreviations and context.

Given their rapid emergence and lack of predictability,
emerging pathogens challenge the current testing paradigm...

An alternate way to manage the continuous threat of
emerging infectious agents is the use of PI technologies
to proactively protect the blood supply and mitigate the
risk of TTIDs. PI = Pathogen Inactivation

The findings of this study are of particular importance
after the US FDA recommended in August 2016 to
1) test all donations collected with a licensed or investigational
individual donor NAT for ZIKV under an investigational
new drug application, 2) to implement pathogen reduction
technology for PLTs and plasma using FDA-approved
devices, or 3) to implement pathogen reduction technology
for whole blood or RBCs if an FDA-approved or
investigational device becomes available.

The amotosalen/UVA systems for plasma and PLTs were
approved by FDA in 2014 and were commercially available
when ZIKV emerged in the Americas and the INTERCEPT
Blood System for PLTs was implemented at the time of the
ZIKV crisis in Puerto Rico in February 2016 to safeguard
and maintain the availability of the blood supply on the island.[60]

The results of this study complement previous results[65]
and show that ZIKV can be inactivated in all blood components
(Table 3) using amotosalen/UVA for PLTs and plasma[41]
and S-303 and GSH for RBCs. The availability of broad spectrum
PI technologies for all blood components enables a new paradigm
for blood safety that can be used to maintain the ongoing
availability and safety of blood products in time of epidemics
with newly emerged and potentially susceptible pathogens.

A great reason to buy while the price is at the $4 mark.... but not for long!!
πŸ‘οΈ0
Harpo1 Harpo1 7 years ago
Hi Guys,

When this hit the wires we should see a good move upward.

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full


Intercept tested on Zika infested blood; And removes from Red Blood Cells!!!!
πŸ‘οΈ0
basssque basssque 7 years ago
No idea on a timeline. I've been day trading it for the past week or so. Movement has been pretty predictable between the teens and twenties.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock